Search | Clinical Trials Finder

Conditions: Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
Interventions: Posaconazole, ABT-199, Decitabine, Azacitidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 60 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 13
States / cities: Duarte, California • Sacramento, California • Aurora, Colorado + 8 more

Conditions: Sickle Cell Disease
Interventions: NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 53
States / cities: Mobile, Alabama • Los Angeles, California • Oakland, California + 37 more

Conditions: Healthy
Interventions: Decitabine; Drug
Lead sponsor: EpiDestiny, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Leukemia
Interventions: Eltrombopag, Decitabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes
Interventions: Decitabine/Cedazuridine, Magrolimab; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: New Haven, Connecticut • Plantation, Florida • Minneapolis, Minnesota

Conditions: Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma
Interventions: chemotherapy, venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 0 Years to 25 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 8 more

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 33
States / cities: Phoenix, Arizona • Costa Mesa, California • Irvine, California + 25 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Interventions: DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine, Venetoclax, GM-CSF; Biological · Drug
Lead sponsor: David Avigan; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: MDS/MPN
Interventions: ASTX727, Itacitinib, Ruxolitinib; Drug
Lead sponsor: Michael Savona; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 4
States / cities: Tampa, Florida • Rochester, New York • Portland, Oregon + 1 more

Conditions: Myelodysplastic Syndromes
Interventions: Oral Azacitidine, Durvalumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 23
States / cities: New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more

Conditions: Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions: INQOVI (decitabine and cedazuridine), Nivolumab; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: Decitabine, Valproic acid; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumor
Interventions: Decitabine, Cedazuridine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Baltimore, Maryland

Conditions: MDS
Interventions: Decitabine; Drug
Lead sponsor: Treebough Therapies; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma
Interventions: Decitabine, Venetoclax, Calaspargase pegol-mknl; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Month to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: AML - Acute Myeloid Leukemia
Interventions: Dexamethasone plus Venetoclax-based Low-Intensity Therapy; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Philadelphia Chromosome Negative Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia
Interventions: decitabine, vorinostat, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Decitabine, Venetoclax, FHD-286; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Acute Myeloid Leukemia
Interventions: ASTX727, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes
Interventions: Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253, Bone Marrow Biopsy, Bone Marrow Aspiration, ECG; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myeloid Malignancy, Acute Myeloid Leukemia
Interventions: Venetoclax, Decitabine; Drug
Lead sponsor: Benjamin Tomlinson; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Myeloproliferative Neoplasm
Interventions: Fedratinib Oral Capsule 300 mg, Decitabine 20 mg/m2, Fedratinib Oral Capsule 400 mg; Drug
Lead sponsor: Joseph Jurcic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia
Interventions: Decitabine, Rapamycin; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
Interventions: Decitabine, Vorinostat, Vincristine, Dexamethasone, Mitoxantrone, Pegaspargase, Methotrexate; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 25
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 20 more

Search by objective public record fields.

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML

Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

BMS-986253 in Myelodysplastic Syndromes

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL